Formation of platinated GG cross-links on DNA by photoactivation of a platinum(IV) azide complex

被引:53
作者
Kaspárková, J
Mackay, FS
Brabec, V
Sadler, PJ
机构
[1] Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland
[2] Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic
来源
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY | 2003年 / 8卷 / 07期
基金
英国工程与自然科学研究理事会; 英国惠康基金;
关键词
cross-links; DNA; guanine; photoactivation; platinum;
D O I
10.1007/s00775-003-0474-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Platinum(II) diam(m)ine complexes such as cisplatin are effective anticancer drugs but have accompanying side effects. We are exploring the design of platinum complexes with low toxicity that could be photoactivated selectively at the target site. We show here that the Pt(IV) azide complex cis,trans-[Pt(en)(N-3)(2)(OH)(2)] is unreactive towards DNA until irradiated with visible light. Transcription mapping studies of a 212-bp fragment of pSP73KB plasmid DNA treated with cis,trans-[Pt(en)(N-3)(2)(OH)(2)] and irradiated with visible light showed that the platination sites were similar to those observed for cisplatin, and were mainly in GG sequences. HPLC analysis of enzymatic digests of an irradiated sample of a 40-bp DNA duplex treated with the same complex also revealed preferential formation of GG cross-links. Since such DNA lesions are thought to be responsible for the induction of apoptosis in cancer cells by platinum drugs, the use of unreactive photoactivatable platinum pro-drugs may become an effective strategy for the design of a new generation of platinum anticancer complexes.
引用
收藏
页码:741 / 745
页数:5
相关论文
共 17 条
[1]   ACTIVATION OF PROGRAMMED CELL-DEATH (APOPTOSIS) BY CISPLATIN, OTHER ANTICANCER DRUGS, TOXINS AND HYPERTHERMIA [J].
BARRY, MA ;
BEHNKE, CA ;
EASTMAN, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) :2353-2362
[2]   DNA INTERSTRAND CROSS-LINKS OF TRANS-DIAMMINEDICHLOROPLATINUM(II) ARE PREFERENTIALLY FORMED BETWEEN GUANINE AND COMPLEMENTARY CYTOSINE RESIDUES [J].
BRABEC, V ;
LENG, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) :5345-5349
[3]   REEVALUATION OF INTERACTION OF CIS-DICHLORO(ETHYLENEDIAMINE)PLATINUM(II) WITH DNA [J].
EASTMAN, A .
BIOCHEMISTRY, 1986, 25 (13) :3912-3915
[4]   CHARACTERIZATION OF THE ADDUCTS PRODUCED IN DNA BY CIS-DIAMMINEDICHLOROPLATINUM(II) AND CIS-DICHLORO(ETHYLENEDIAMINE)PLATINUM(II) [J].
EASTMAN, A .
BIOCHEMISTRY, 1983, 22 (16) :3927-3933
[6]   ADDUCTS OF THE ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II) WITH DNA - FORMATION, IDENTIFICATION, AND QUANTITATION [J].
FICHTINGERSCHEPMAN, AMJ ;
VANDERVEER, JL ;
DENHARTOG, JHJ ;
LOHMAN, PHM ;
REEDIJK, J .
BIOCHEMISTRY, 1985, 24 (03) :707-713
[7]   Structure, recognition, and processing of cisplatin-DNA adducts [J].
Jamieson, ER ;
Lippard, SJ .
CHEMICAL REVIEWS, 1999, 99 (09) :2467-2498
[8]   Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross-linking [J].
Kaspárková, J ;
Nováková, O ;
Vrána, O ;
Farrell, N ;
Brabec, V .
BIOCHEMISTRY, 1999, 38 (34) :10997-11005
[9]   Synthesis and X-ray crystal structure of trans,cis-[Pt(OAc)(2)I-2(en)]: A novel type of cisplatin analog that can be photolyzed by visible light to DNA-binding and cytotoxic species in vitro [J].
Kratochwil, NA ;
Zabel, M ;
Range, KJ ;
Bednarski, PJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (13) :2499-2507
[10]  
Kratochwil NA, 1996, ANTI-CANCER DRUG DES, V11, P155